Atherosclerosis and inflammation. New therapeutic approaches.

Juan Pedro-Botet, Elisenda Climent, David Benaiges

Journal: Medicina clinica 2021;155(6):256-262

PMID: 32571617

Full Text on Ediciones Doyma, S.L. View on PubMed

Abstract

The recognition of atherogenesis as an active process rather than a passive cholesterol storage disease has underlined key inflammatory mechanisms. Hence, innate and adaptive immune responses play an important role in the onset and progression of atherosclerosis. More recently, some clinical studies were designed to address the impact of anti-inflammatory intervention strategies in reducing risk of cardiovascular disease beyond the management of classic risk factors. Therefore, we review first the pathophysiological contribution of inflammation to atherosclerosis and the effect of lipid-lowering drugs on inflammatory biomarkers. Next, we address the effect of classic anti-inflammatory drugs, pharmacological therapies targeting specific inflammatory mediators and vaccines in cardiovascular prevention.

Address: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España. Electronic address: [email protected].; Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España.

DOI: 10.1016/j.medcli.2020.04.024

Link outs

Free resources

Medical:

https://medlineplus.gov/atherosclerosis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Anti-Inflammatory Agents, Atherosclerosis, Biomarkers, Humans, Inflammation, Inflammation Mediators